Information
CH-223191 CH-223191 is a potent and specific aryl hydrocarbon receptor (AhR) antagonist with IC50 of 30 nM.
In vitro
CH-223191 blocks TCDD-mediated nuclear translocation and DNA binding of AhR, and also causes the inhibition of TCDD-induced cytochrome P450 enzyme activity. In human glioblastoma cells, CH-223191downregulates the TGF-beta/Smad pathway, and reduces clonogenic survival and invasiveness. In SK-N-SH human-derived neuronal cells, CH223191 counteracts the TCDD-induced suppression of neuronal acetylcholinesterase expression. In endothelial cells, CH-223191 potentiates ICAM-1 expression and prevents RelB nuclear translocation.
In vivo
CH-223191 (10 mg/kg/day, p.o.) potently prevents TCDD-caused cytochrome P450 induction, liver toxicity, and wasting syndrome in mice.
Cell Data
cell lines：PAE
Concentrations：
Incubation Time：
Powder Purity:≥99%
| Isómeros SMILES | CC1=CC=CC=C1N=NC2=CC(=C(C=C2)NC(=O)C3=CC=NN3C)C |
|---|---|
| Peso molecular | 333.39 |
| Reaxy-Rn | 10571968 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=10571968&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Fecha | Articulo |
|---|---|---|---|
 G2412004 | Certificate of Analysis | May 19, 2026 | C408298 |
| 1. Yang Yang, Yue Tao, Xiaodong Yi, Guanyu Zhong, Yanyan Gu, Yunhe Cui, Ying Zhang. (2023) Crosstalk between aryl hydrocarbon receptor and Wnt/β-catenin signaling pathway: Possible culprit of di (2-ethylhexyl) phthalate-mediated cardiotoxicity in zebrafish larvae. SCIENCE OF THE TOTAL ENVIRONMENT, [PMID:37866606] [10.1016/j.scitotenv.2023.167907] |
| 2. Jiani Zhan, Yijia Chen, Yuying Liu, Yunqiu Chen, Zhiyao Li, Xuewen Li, Zhenning He, Fangzhou Meng, Xiaoyang Qian, Lili Yang, Qing Yang. (2025) IDO1-mediated AhR activation up-regulates pentose phosphate pathway via NRF2 to inhibit ferroptosis in lung cancer. BIOCHEMICAL PHARMACOLOGY, [PMID:40164341] [10.1016/j.bcp.2025.116913] |
| 3. Yunqiu Chen, Jiayun Ying, Zhiyao Li, Zhen Ning Tony He, Jiani Zhan, Heng Liang, Yuying Liu, Yijia Chen, Xuewen Li, Ting Zhu, Chunxiang Kuang, Guoping Lu, Qing Yang. (2025) IDO1 inhibitors block septic cytokine storm by suppressing the IDO1-AHR-CYP1A1 axis. BIOMEDICINE & PHARMACOTHERAPY, [PMID:40245547] [10.1016/j.biopha.2025.118054] |
| 4. Yang Chuan, Xie Langlang, Deng Zihan, Ai Hongbo, Xiang Tingwen, Yan Xiaojing, Ling Zhiguo, Xiao Shiyu, Tang Yong, Huang Gang, Luo Fei, Chen Yueqi. (2025) An orally-administered nanotherapeutics with gold nanospheres supplying for rheumatoid arthritis therapy by re-shaping gut microbial tryptophan metabolism. JOURNAL OF NANOBIOTECHNOLOGY, 23 (1): (1-22). [PMID:40414887] [10.1186/s12951-025-03450-7] |
| 5. Nan Zhao, Wei Song, Tianshu Sun, Weiwei Wu, Yongliang Feng, Ning Ma, Suping Wang. (2025) Nicotinamide metabolic dysregulation plays a key role in Benzo[a]pyrene-induced adverse birth outcomes: Evidence from multi-omics profiling, experimental and epidemiological validation. JOURNAL OF HAZARDOUS MATERIALS, [PMID:41032930] [10.1016/j.jhazmat.2025.140000] |
